研究单位：[1]Ruijin Hospital[2]Beljing Tiantan Hospital, Capttal Medical, University,Beijing,China[3]Xuanwu Hospital Capital Medical University,Beijing,China[4]Sun Yat-Sen University Cancer Center,Guangzhou,China[5]Henan Cancer Hospital,Henan,China[6]Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai,China[7]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,,Wuhan,China
研究目的：
This study aims to evaluate the efficacy and safety of Relma-cel in the treatment of central nervous system lymphoma (CNSL), as well as its pharmacokinetic characteristics. Enrolled patients with relapsed/refractory (R/R) CNSL will receive Relma-cel infusion, followed by Tislelizumab treatment (200mg, IV, q4w, for 12 months) starting on day 35 after infusion. Bruton's tyrosine kinase (BTK) inhibitors will be used in combination as needed. The follow-up period will last for 4 years, monitoring drug safety, disease status, survival, and the pharmacokinetic characteristics of Relma-cel.
